{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-109158","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.460736+00:00","generated_at":"2026-05-16T22:32:02.592599+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Passage Bio Q3 net loss $7.7M; cash runway into 1Q 2027; FTD trial enrollment ongoing","bullets":["Cash and marketable securities $52.8M as of Sep 30, 2025; expected to fund operations into 1Q 2027.","Net loss narrowed to $7.7M ($2.44 per share) vs $19.3M ($6.15) in Q3 2024; R&D and G&A expenses declined.","Enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) in upliFT-D study; interim data expected in 1H 2026.","Aligned with FDA on analytical comparability plan for suspension-based PBFT02 manufacturing process.","On track for FDA feedback on FTD-GRN registrational trial design in 1H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-109158","json":"https://secwatch.observer/filing/0001104659-25-109158.json","markdown":"https://secwatch.observer/filing/0001104659-25-109158.md","text":"https://secwatch.observer/filing/0001104659-25-109158.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000110465925109158/0001104659-25-109158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000110465925109158/pasg-20251110x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:32:02.592599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}